Real‐world antiseizure medication prescribing and treatment pathways in a pediatric health care system
Year: 2026
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: To characterize antiseizure medication (ASM) selection, subsequent ASM prescribing, and treatment pathways among patients with epilepsy receiving care within a pediatric health care system. METHODS: We conducted a retrospective electronic health record study over 17 years. Each unique ASM was counted once per patient, and ASMs were ordered by the date of their first observed prescription. For each observed ASM, we determined whether a subsequent unique ASM was prescribed during available follow-up. Prescription of a third unique ASM was used as a proxy for potential drug-resistant epilepsy. RESULTS: Among 20 009 patients, 27 ASMs and 3507 treatment pathways were identified. The most common first-observed ASMs were levetiracetam (35.1%), oxcarbazepine (17.2%), and valproic acid (12.3%). From 2010 to 2026, the proportion of first-observed prescriptions for levetiracetam increased from 23.1% to 41.5%. The proportion of all distinct ASMs first recorded for individual patients that were newer-generation ASMs increased from 0% in 2010 to 9.1% in 2026. The proportion of patients without a subsequent ASM ranged from 16.2% to 69.6% across commonly prescribed first-observed ASMs. Overall, 55.6% of patients had one unique ASM recorded, 22.4% had two, and 22.0% had at least three, thereby meeting the study's prescription-based proxy for potential drug-resistant epilepsy. Beyond the most common single- and two-ASM pathways, each remaining pathway accounted for less than 1% of the cohort. SIGNIFICANCE: Prescribing remained concentrated among established ASMs, although their relative use changed substantially. The proportion of patients without a subsequent ASM varied widely across medications, and treatment pathways beyond first-observed therapy were highly heterogeneous. These findings characterize real-world treatment patterns and identify a need for comparative effectiveness studies of ASM sequencing. PLAIN LANGUAGE SUMMARY: We examined antiseizure medication prescribing over 17 years among more than 20 000 patients with epilepsy receiving care in a pediatric health care system. More than half had only one medication recorded, whereas 22% had at least three medications; however, the available records could not determine whether these medications failed to control seizures. Levetiracetam became more commonly prescribed, newer medications remained a small proportion of overall use, and medication sequences varied widely after the first observed treatment. These findings highlight the need for better evidence to guide medication selection after initial treatment.
Source: Epilepsia Open
DOI: 10.1002/epi4.70380
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: antiepileptic drugs, pediatric epilepsy, prescribing patterns, treatment pathways, drug-resistant epilepsy, levetiracetam, oxcarbazepine, valproic acid, comparative effectiveness, real-world evidence, health care utilization, health care costs, health care access, quality of care, health care equity
Open Access status: gold
Estimated APC paid: $3,120
OpenAlex ID: W7229700468
